Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
Liang En Wee, An Ting Tay, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 10, pp. 1328-1333
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Severity of respiratory syncytial virus versus SARS-CoV-2 Omicron and influenza infection amongst hospitalized Singaporean adults: a national cohort study
Liang En Wee, Jue Tao Lim, Rth Ho, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 55, pp. 101494-101494
Open Access | Times Cited: 1
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
The Lancet Regional Health - Americas (2024) Vol. 31, pp. 100693-100693
Open Access | Times Cited: 7
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 5
A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease
Liang En Wee, Janice Yu Jin Tan, Calvin J. Chiew, et al.
CHEST Journal (2024) Vol. 166, Iss. 4, pp. 685-696
Closed Access | Times Cited: 5
Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 10, pp. 1319-1326
Closed Access | Times Cited: 5
Risks of Severe Acute Respiratory Syndrome Coronavirus 2 JN.1 Infection and Coronavirus Disease 2019–Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study
Cheryl Chong, Liang En Wee, Xuan Jin, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 5, pp. 1190-1196
Closed Access | Times Cited: 4
Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 4
The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19
Jheng‐Yan Wu, Mei‐Yuan Liu, Mei-Chuan Lee, et al.
Expert Review of Anti-infective Therapy (2024), pp. 1-10
Closed Access | Times Cited: 3
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 7
Oral antiviral utilisation among older adults with COVID-19 in primary care: A population-wide study during successive Omicron waves in Singapore
Ren Ying Tan, Borame Sue Lee Dickens, Joyce Tan, et al.
Annals of the Academy of Medicine Singapore (2024) Vol. 53, Iss. 2, pp. 117-120
Open Access | Times Cited: 2
Dengue versus COVID-19: comparing the incidence of cardiovascular, neuropsychiatric and autoimmune complications
Liang En Wee, Jue Tao Lim, Janice Yu Jin Tan, et al.
Journal of Travel Medicine (2024) Vol. 31, Iss. 5
Closed Access | Times Cited: 2
Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune‐suppressive drugs: A nationwide cohort study of US Veterans
Sonia T. Anand, Austin D. Vo, Jennifer La, et al.
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 5
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
Adeel A. Butt, Yan Peng, Obaid S. Shaikh, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 1, pp. 147-154
Open Access | Times Cited: 4
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Chi‐Kuei Hsu, Wan‐Hsuan Hsu, Bo-Wen Shiau, et al.
Expert Review of Anti-infective Therapy (2024), pp. 1-8
Closed Access | Times Cited: 1
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert)
Isolde Sommer, Andreea Dobrescu, Emma Persad, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8
Closed Access | Times Cited: 1
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
Nan Shang, Xianlin Li, Zhiyu Guo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Effects of recent prior dengue infection on risk and severity of subsequent SARS-CoV-2 infection: a retrospective cohort study
Nicole K. Y. Tang, Jue Tao Lim, Borame Sue Lee Dickens, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 8
Open Access | Times Cited: 1
Insights from a community-based survey on factors Influencing Acceptance and Uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 Antiviral Medication in Singapore
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, et al.
Research Square (Research Square) (2024)
Open Access
Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access
Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan
Shuhei Ideguchi, Kazuya Miyagi, Wakaki Kami, et al.
PLoS ONE (2024) Vol. 19, Iss. 10, pp. e0309808-e0309808
Open Access
Response
Liang En Wee, Janice Yu Jin Tan, Calvin J. Chiew, et al.
CHEST Journal (2024) Vol. 166, Iss. 5, pp. e167-e168
Closed Access
COVID-19 residual symptoms and adverse drug reactions after oral antiviral therapy in the Singapore primary care setting
Jia Qi Yeo, Poh Ching Tan, Cheng Tan, et al.
Annals of the Academy of Medicine Singapore (2024) Vol. 53, Iss. 12, pp. 762-764
Open Access
Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico
María Elena Camacho-Moll, Ana María Salinas‐Martínez, Minna Wu, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 7, pp. 102444-102444
Open Access
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
Keita Kawashiro, Rigel Suzuki, Takuto Nogimori, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Utilization of Real-World Data in Drug Development
Lu Hao
Proceedings of Anticancer Research (2024) Vol. 8, Iss. 3, pp. 109-114
Open Access
Page 1 - Next Page

Scroll to top